| HOME >> MEDICINE >> TECHNOLOGY |
Table 25: China - top 10 selling traditional Chinese medicines in hospital prescription drug market (China and Hong Kong), 2009 120
Table 26: China - hospital sales growth ($m and %) for top 20 pharmaceutical brands (China and Hong Kong), 2009 122
Table 27: China - hospital volume growth (SUm and %) for top 20 pharmaceutical brands (China and Hong Kong), 2009 123
Table 28: China - hospital sales growth ($ and %) for the leading pharmaceutical companies (China and Hong Kong), 2009 127
Table 29: China - hospital volume growth (SUm and %) for the leading pharmaceutical companies (China and Hong Kong), 2009 128
Table 30: China - hospital sales growth ($m and %) for the leading Chinese pharmaceutical companies (China and Hong Kong), 2009 129
Table 31: China - hospital volume growth (SUm and %) for the leading Chinese pharmaceutical companies (China and Hong Kong), 2009 130
Table 32: China - Shandong Qilu Pharma's top 10 selling drugs ($m) and their NRDL status (China and Hong Kong), 2010 131
Table 33: China - Jiangsu Yangzijiang Pharma's top 10 selling drugs ($m) and their NRDL status (China and Hong Kong), 2010 132
Table 34: China - key metrics for the generics and biologics/biosimilars market, 2010 134
Table 35: China - comparison of generic penetration versus other major pharmaceutical markets ($ billion and %), 2007-08 137
Table 36: China - leading domestic and foreign generics companies in the hospital segment, 2009 145
Table 37: China - hospital sales and market share ($m and %) of domestically and internationally developed biologics (China and Hong Kong), 2009 148
Table 38: China - hospital sales($m) for the top10 domestic/biologics manufacturers (China and Hong Kong), 2009 151
Table 39: China - global and domestic sales ($m) for the top 10 biologics (China and Hong Kong hospital sales), 2009 152
Table 40: China - launched and developmental biosimilars in
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |